VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TMOThermo Fisher Scientific Inc.
$464.61$172.7B
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTMOP/E History

TMO logoThermo Fisher Scientific Inc. (TMO) P/E Ratio History

Undervalued

Trading at 26.2x vs 5Y avg 31.3x · 15th percentile · Below historical baseline · Data 1990–2026

Current P/E (TTM)
26.2x
-16% vs 5Y avg
5Y Avg P/E
31.3x
Median 31.5x
5Y Percentile
15th
Lower end of range
PEG Ratio
12.40
Premium to growth
5-Year P/E Range
26.2x
Min23.6xMedian31.5xMax38.5x
TTM EPS$18.39
Price$464.61
Earnings Yield3.82%
EPS Growth (1Y)7.3%
EPS Growth (5Y)2.1%

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Thermo Fisher Scientific Inc. (TMO) trades at a price-to-earnings ratio of 26.2x, with a stock price of $464.61 and trailing twelve-month earnings per share of $18.39.

The current P/E is 16% below its 5-year average of 31.3x. Over the past five years, TMO's P/E has ranged from a low of 23.6x to a high of 38.5x, placing the current valuation at the 15th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, TMO trades at a 18% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 12.40 (P/E divided by 7% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, TMO trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TMO DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

TMO Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
26.2vs22.1
+18%
Above Sector
vs. S&P 500
26.2vs24.4
+7%
In Line with Market
PEG Analysis
12.40
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 7% EPS growth (1Y)

TMO P/E vs Peers

Life Science Instruments and Sequencing Tools peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
DHR logoDHRDanaher Corporation
$125B35.2--5%
A logoAAgilent Technologies, Inc.
$36B27.81.89+3%
WAT logoWATWaters Corporation
$23B33.06.38+0%
BIO logoBIOBio-Rad Laboratories, Inc.
$8B10.1Lowest-+143%Best
MTD logoMTDMettler-Toledo International Inc.
$23B27.12.45+4%
IQV logoIQVIQVIA Holdings Inc.
$28B21.40.53Best+5%
MEDP logoMEDPMedpace Holdings, Inc.
$13B30.10.95+21%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

TMO Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1Mar 28 2026$473.36$18.1926.0x-54%
FY2025 Q4Dec 31 2025$579.45$17.7432.7x-42%
FY2025 Q3Sep 27 2025$464.24$17.3126.8x-52%
FY2025 Q2Jun 28 2025$408.28$17.2823.6x-58%
FY2025 Q1Mar 29 2025$500.16$17.0429.4x-48%
FY2024 Q4-$520.23$16.5231.5x-44%
FY2024 Q3Sep 28 2024$614.42$15.9438.5x-32%
FY2024 Q2Jun 29 2024$553.00$16.1234.3x-39%
FY2024 Q1Mar 30 2024$581.21$15.5937.3x-34%
FY2023 Q4Dec 31 2023$530.79$15.4534.4x-39%
FY2023 Q3Sep 30 2023$506.17$15.2633.2x-41%
FY2023 Q2Jul 01 2023$521.75$14.6235.7x-37%
FY2023 Q1Apr 01 2023$576.37$15.3337.6x-33%
FY2022 Q4Dec 31 2022$550.69$17.6231.3x-45%
FY2022 Q3Oct 01 2022$507.19$17.7828.5x-49%
FY2022 Q2Jul 02 2022$548.27$18.7929.2x-48%
FY2022 Q1Apr 02 2022$592.34$19.1830.9x-45%
FY2021 Q4Dec 31 2021$667.24$19.4534.3x-39%
FY2021 Q3Oct 02 2021$572.72$21.5226.6x-53%
FY2021 Q2Jul 03 2021$513.32$21.5723.8x-58%
FY2021 Q1Apr 03 2021$456.30$19.8623.0x-59%
FY2020 Q4-$465.78$15.9529.2x-48%
FY2020 Q3Sep 26 2020$422.29$12.2034.6x-39%
FY2020 Q2Jun 27 2020$350.95$9.2438.0x-33%
FY2020 Q1Mar 28 2020$274.34$9.1130.1x-47%
FY2019 Q4-$324.87$9.1635.5x-37%
FY2019 Q3Sep 28 2019$287.40$8.8932.3x-43%
FY2019 Q2Jun 29 2019$293.68$8.7633.5x-41%
FY2019 Q1Mar 30 2019$273.72$7.8434.9x-38%
FY2018 Q4Dec 31 2018$223.79$7.2530.9x-45%
FY2018 Q3Sep 29 2018$244.08$6.3338.6x-32%
FY2018 Q2Jun 30 2018$207.14$5.9235.0x-38%
FY2018 Q1Mar 31 2018$206.46$5.6336.7x-35%
FY2017 Q4Dec 31 2017$189.88$5.6033.9x-40%
FY2017 Q3Sep 30 2017$189.20$5.8932.1x-43%
FY2017 Q2Jul 01 2017$174.47$5.7430.4x-46%
FY2017 Q1Apr 01 2017$153.60$5.4828.0x-50%
FY2016 Q4Dec 31 2016$141.10$5.0927.7x-51%
FY2016 Q3Oct 01 2016$159.06$5.0031.8x-44%
FY2016 Q2Jul 02 2016$149.23$4.9929.9x-47%
FY2016 Q1Apr 02 2016$142.67$4.9628.8x-49%
FY2015 Q4-$141.85$4.9128.9x-49%
FY2015 Q3Sep 26 2015$122.65$4.9125.0x-56%
FY2015 Q2Jun 27 2015$132.21$4.9027.0x-52%
FY2015 Q1Mar 28 2015$133.69$4.3230.9x-45%
FY2014 Q4Dec 31 2014$125.29$4.7226.5x-53%
FY2014 Q3Sep 27 2014$121.36$4.1429.3x-48%
FY2014 Q2Jun 28 2014$118.30$3.8330.9x-45%
FY2014 Q1Mar 29 2014$118.50$3.9030.4x-46%
FY2013 Q4-$111.35$3.4732.1x-43%
FY2013 Q3Sep 28 2013$93.01$3.5925.9x-54%
FY2013 Q2Jun 29 2013$84.63$3.5224.0x-57%
FY2013 Q1Mar 30 2013$76.49$3.3922.6x-60%
FY2012 Q4Dec 31 2012$63.78$3.9616.1x-71%
FY2012 Q3Sep 29 2012$58.83$3.6915.9x-72%
FY2012 Q2Jun 30 2012$51.91$3.5914.5x-74%
FY2012 Q1Mar 31 2012$56.38$4.3213.1x-77%
FY2011 Q4Dec 31 2011$44.97$3.4613.0x-77%
FY2011 Q3Oct 01 2011$50.64$3.4414.7x-74%
FY2011 Q2Jul 02 2011$65.01$3.4119.1x-66%
FY2011 Q1Apr 02 2011$55.98$2.6221.4x-62%
FY2010 Q4Dec 31 2010$55.36$2.5421.8x-61%
FY2010 Q3Oct 02 2010$47.82$2.4419.6x-65%
FY2010 Q2Jul 03 2010$47.58$2.3120.6x-63%
FY2010 Q1Apr 03 2010$51.77$2.2323.2x-59%
FY2009 Q4-$47.69$2.0223.6x-58%
FY2009 Q3Sep 26 2009$44.00$2.0521.5x-62%
FY2009 Q2Jun 27 2009$41.91$2.0220.7x-63%
FY2009 Q1-$35.67$2.1017.0x-70%
FY2008 Q4Dec 31 2008$34.07$2.2814.9x-74%
FY2008 Q3Sep 27 2008$56.62$2.1526.3x-53%
FY2008 Q2Jun 28 2008$55.32$2.1425.9x-54%
FY2008 Q1Mar 29 2008$56.44$1.9429.1x-48%
FY2007 Q4Dec 31 2007$57.68$1.7233.5x-41%
FY2007 Q3Sep 29 2007$57.72$1.2347.0x-17%
FY2007 Q2Jun 30 2007$51.72$1.0449.9x-12%
FY2007 Q1Mar 31 2007$46.75$0.9648.9x-13%
FY2006 Q4Dec 31 2006$45.29$0.9348.9x-13%
FY2006 Q3Sep 30 2006$39.33$1.2132.5x-42%
FY2006 Q2Jul 01 2006$36.24$1.2628.8x-49%
FY2006 Q1Apr 01 2006$37.09$1.3427.7x-51%
FY2005 Q4Dec 31 2005$30.13$1.3622.2x-61%
FY2005 Q3Oct 01 2005$30.90$1.7617.6x-69%
FY2005 Q2Jul 02 2005$26.80$2.0613.0x-77%
FY2005 Q1Apr 02 2005$25.00$2.2311.2x-80%
FY2004 Q4Dec 31 2004$30.19$2.1713.9x-75%
FY2004 Q3Oct 02 2004$28.07$1.7915.7x-72%
FY2004 Q2Jul 03 2004$29.69$1.4320.8x-63%
FY2004 Q1Apr 03 2004$29.33$1.2124.2x-57%
FY2003 Q4Dec 31 2003$25.20$1.1921.2x-62%
FY2003 Q3Sep 27 2003$21.72$1.3616.0x-72%
FY2003 Q2Jun 28 2003$21.42$1.3016.5x-71%
FY2003 Q1Mar 29 2003$18.10$1.3613.3x-76%
FY2002 Q4-$20.12$1.7311.6x-79%
FY2002 Q3Sep 28 2002$16.27$1.1713.9x-75%
FY2002 Q2Jun 29 2002$16.50$1.0815.3x-73%
FY2002 Q1Mar 30 2002$20.73$0.8424.8x-56%
FY2001 Q4Dec 31 2001$23.86$0.013728.1x+6509%
FY2000 Q3Sep 30 2000$22.36$0.2975.9x+35%
FY2000 Q2Jul 01 2000$18.11$0.4440.7x-28%
FY1999 Q1Apr 03 1999$11.61$0.8314.0x-75%
FY1998 Q4-$14.56$1.0314.1x-75%
FY1998 Q3Oct 03 1998$12.90$1.2010.8x-81%
FY1998 Q2Jul 04 1998$30.36$1.4620.8x-63%
FY1998 Q1Apr 04 1998$35.36$1.4724.1x-57%
FY1997 Q4Dec 31 1997$37.83$1.4226.6x-53%
FY1997 Q3Sep 27 1997$33.70$1.3624.8x-56%
FY1997 Q2Jun 28 1997$29.34$1.3222.2x-61%
FY1997 Q1Mar 29 1997$28.05$1.2921.7x-61%
FY1996 Q4-$35.47$1.1830.1x-47%
FY1996 Q3Sep 28 1996$34.72$1.1330.7x-46%
FY1996 Q2Jun 29 1996$35.79$0.9936.2x-36%
FY1996 Q1Mar 30 1996$34.32$0.8241.9x-26%
FY1995 Q4Dec 31 1995$29.81$0.7241.4x-27%
FY1995 Q3Sep 30 1995$26.58$0.6839.1x-31%
FY1995 Q2Jul 01 1995$23.07$0.5938.9x-31%
FY1995 Q1Apr 01 1995$19.44$0.5336.8x-35%
FY1994 Q4Dec 31 1994$17.15$0.5034.2x-39%
FY1994 Q3Oct 01 1994$17.53$0.4737.1x-34%
FY1994 Q2Jul 02 1994$14.33$0.4333.2x-41%
FY1994 Q1Apr 02 1994$14.86$0.4037.3x-34%
FY1993 Q4Dec 31 1993$16.05$0.3644.8x-21%
FY1993 Q3-$16.18$0.3447.9x-15%
FY1993 Q2Jun 30 1993$15.13$0.3346.0x-19%
FY1993 Q1Mar 31 1993$14.33$0.3244.3x-21%
FY1992 Q4-$12.01$0.3237.5x-34%
FY1992 Q3Sep 30 1992$10.54$0.2936.3x-36%
FY1992 Q2-$10.38$0.2935.8x-37%
FY1992 Q1-$9.78$0.2834.4x-39%
FY1991 Q4-$11.88$0.2843.1x-24%
FY1991 Q3Sep 30 1991$10.25$0.2640.1x-29%
FY1991 Q2Jun 30 1991$9.24$0.2537.0x-34%
FY1991 Q1Mar 31 1991$8.73$0.2435.8x-36%
FY1990 Q4Dec 31 1990$7.36$0.2431.0x-45%
FY1990 Q3Sep 30 1990$5.86$0.2226.9x-52%

Average P/E for displayed period: 56.4x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into TMO consensus models and risk factors.

View Analysis

Should I Buy TMO?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TMO — Frequently Asked Questions

Quick answers to the most common questions about buying TMO stock.

What is TMO's P/E ratio?

Thermo Fisher Scientific Inc. (TMO) trailing twelve-month P/E ratio is 26.2x, based on TTM diluted EPS of $18.39. The 5-year average P/E is 31.3x and the historical range spans 23.6x to 38.5x.

Is TMO stock overvalued or undervalued?

TMO trades at 26.2x P/E, near its 5-year average of 31.3x. The 15th percentile ranking within the 23.6x–38.5x historical range places valuation within normal bounds.

Is TMO stock expensive?

TMO is fairly valued relative to its own history. The current P/E of 26.2x is near the 5-year average of 31.3x (15th percentile of historical range).

What is TMO's historical P/E range?

Over the past 5 years, TMO's P/E ratio has ranged from 23.6x to 38.5x, with a median of 31.5x and an average of 31.3x. The current P/E of 26.2x places the stock at the 15th percentile of this range. Full historical data spans 1990–2026.

How does TMO's P/E compare to the S&P 500?

TMO trades at 26.2x P/E versus the S&P 500 median of 24.4x. The 7% premium to the market typically reflects higher expected earnings growth or quality.

How does TMO's valuation compare to Healthcare peers?

Thermo Fisher Scientific Inc. P/E of 26.2x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is TMO's PEG ratio?

TMO PEG ratio is 12.40, based on a P/E of 26.2x and EPS growth of 7.3%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is TMO's earnings yield?

TMO earnings yield is 3.82%, the inverse of its 26.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

TMO P/E Ratio History (1990–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current26.0x
Period Avg31.3x
Range23.6x - 38.5x
Change+9%
20 quartersJul 3, 2021 - Mar 28, 2026